Sangamo Therapeutics (SGMO) Receivables - Other (2016 - 2024)
Sangamo Therapeutics (SGMO) has 15 years of Receivables - Other data on record, last reported at $4.1 million in Q4 2024.
- For Q4 2024, Receivables - Other rose 917.37% year-over-year to $4.1 million; the TTM value through Dec 2024 reached $4.1 million, up 917.37%, while the annual FY2024 figure was $4.1 million, 917.37% up from the prior year.
- Receivables - Other reached $4.1 million in Q4 2024 per SGMO's latest filing, down from $10.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $10.0 million in Q3 2024 and bottomed at $289000.0 in Q2 2022.
- Average Receivables - Other over 5 years is $1.4 million, with a median of $800500.0 recorded in 2021.
- Peak YoY movement for Receivables - Other: tumbled 66.28% in 2021, then surged 1561.13% in 2024.
- A 5-year view of Receivables - Other shows it stood at $1.0 million in 2020, then plummeted by 66.28% to $349000.0 in 2021, then skyrocketed by 127.51% to $794000.0 in 2022, then tumbled by 49.24% to $403000.0 in 2023, then skyrocketed by 917.37% to $4.1 million in 2024.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $4.1 million in Q4 2024, $10.0 million in Q3 2024, and $403000.0 in Q4 2023.